Announcements Trials
Browse Landscape

Phase

Phase 1 19Phase 2 10Phase 1/2 5Phase EARLY_PHASE1 2Phase 2/3 2Phase NA 1Phase 3 1

Status

Recruiting 2Terminated 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 4NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Sarcoma 5CNS 5

Conditions

Carcinoma, Non-Small-Cell Lung 255Breast Neoplasms 172Neoplasms 167Colorectal Neoplasms 154Neoplasm Metastasis 127Melanoma 119Recurrence 116Prostatic Neoplasms 116Leukemia, Myeloid, Acute 115Pancreatic Neoplasms 113Ovarian Neoplasms 110Multiple Myeloma 103Lung Neoplasms 95Stomach Neoplasms 89Squamous Cell Carcinoma of Head and Neck 83Triple Negative Breast Neoplasms 81Glioblastoma 81Lymphoma 77Lymphoma, Non-Hodgkin 75Lymphoma, Large B-Cell, Diffuse 64Carcinoma, Renal Cell 64Precursor Cell Lymphoblastic Leukemia-Lymphoma 62Advanced Solid Tumor 59Endometrial Neoplasms 58Carcinoma, Hepatocellular 57Small Cell Lung Carcinoma 54Sarcoma 52Uterine Cervical Neoplasms 51Myelodysplastic Syndromes 51Leukemia 49

Interventions

atezolizumab 2Temozolomide 2pembrolizumab 1cabozantinib 1Sonication 1Radiotherapy 1Radiation 1Drug Therapy 1Carboplatin 1Albumin-Bound Paclitaxel 114-methyl-20-oxa-5,7,14,26-tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1/2 × Gliosarcoma × 1 year × Clear all
NCT04528680 2026-04-13

SC9/ABX

Northwestern University

Phase 1/2 Active not recruiting
57 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

NCT02942264 2026-02-23

Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
53 enrolled 22 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Recurrence, Gliosarcoma

NCT05084430 2026-01-22

Study of Pembrolizumab and M032 (NSC 733972)

University of Alabama at Birmingham

Phase 1/2 Recruiting
28 enrolled
CNSSarcoma

Astrocytoma, Glioblastoma, Recurrence, Gliosarcoma

NCT05039281 2025-12-19

Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
6 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

NCT03174197 2025-09-24

Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

M.D. Anderson Cancer Center

Phase 1/2 Completed
60 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡